Free Trial Information
BioCentury | Jun 18, 2015
Distillery Techniques

Techniques: Crystal structure of myeloid leukemia cell differentiation protein (MCL1)

...inhibitors. (See "Watershed Crystal", page 16) Teva Pharmaceutical Industries Ltd. and Hospira Inc. market Synribo omacetaxine mepesuccinate...
Read More
BioCentury | Apr 30, 2015
Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); B cell lymphoma 2 (BCL-2; BCL2); Bcl-XL

...cancer cell lines and animal models. Teva Pharmaceutical Industries Ltd. and Hospira Inc. market Synribo omacetaxine mepesuccinate...
Read More
BioCentury | May 12, 2014
Clinical News

Synribo omacetaxine mepesuccinate regulatory update

...FDA approved an updated label for Synribo omacetaxine mepesuccinate from Teva to allow home administration of the...
...intolerance to >=2 tyrosine kinase inhibitors (TKIs). Previously, patients had to receive subcutaneous injections of Synribo...
...Petah Tikva, Israel Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Product: Synribo omacetaxine mepesuccinate (formerly Omapro , Ceflatonin...
Read More
BioCentury | Apr 7, 2014
Finance

1Q Stock Wrap-Up: Small but mighty

...drug Copaxone glatiramer acetate Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) FDA grants full approval to Synribo omacetaxine mepesuccinate...
...and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). FDA granted accelerated approval to Synribo...
Read More
BioCentury | Feb 17, 2014
Clinical News

Synribo omacetaxine mepesuccinate regulatory update

...FDA granted full approval to Teva's Synribo omacetaxine mepesuccinate to treat chronic or accelerated phase chronic myelogenous...
...with resistance and/or intolerance to >=2 tyrosine kinase inhibitors (TKIs). FDA granted accelerated approval to Synribo...
...Petah Tikva, Israel Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Product: Synribo omacetaxine mepesuccinate (formerly Omapro , Ceflatonin...
Read More
BioCentury | Feb 14, 2014
Company News

FDA grants full approval to Teva's Synribo

...FDA granted full approval to Synribo omacetaxine mepesuccinate from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to treat chronic...
...and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). FDA granted accelerated approval to Synribo...
Read More
BioCentury | Sep 2, 2013
Strategy

Back to School 2013: Facing reality

For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector, FDA , EMA and Japan's Pharmaceuticals and Medical Devices Agency are...
Read More
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

...Corp. (TSX:TKM; NASDAQ:TKMR) Marqibo vincristine Philadelphia chromosome-negative ALL U.S. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Synribo omacetaxine mepesuccinate...
Read More
BioCentury | Jan 7, 2013
Finance

4Q Stock Wrap-Up: Go big or go home

...in adults and children 6-17 years old Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) FDA approves Synribo omacetaxine mepesuccinate...
Read More
BioCentury | Oct 29, 2012
Finance

Highlights of weekly biotech stock moves

...response letter for another. On Friday, FDA granted accelerated approval to an NDA for Synribo omacetaxine mepesuccinate...
Read More
Items per page:
1 - 10 of 108